Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Jul 27, 2023

BUY
$0.57 - $1.08 $18,260 - $34,598
32,036 New
32,036 $19,000
Q4 2022

Feb 15, 2023

BUY
$1.1 - $2.45 $5,420 - $12,073
4,928 Added 18.29%
31,867 $40,000
Q3 2022

Nov 07, 2022

SELL
$1.96 - $3.32 $5,678 - $9,618
-2,897 Reduced 9.71%
26,939 $55,000
Q2 2022

Aug 09, 2022

BUY
$2.27 - $4.86 $14,775 - $31,633
6,509 Added 27.9%
29,836 $83,000
Q1 2022

May 17, 2022

BUY
$3.69 - $5.65 $86,076 - $131,797
23,327 New
23,327 $102,000
Q1 2021

May 19, 2021

SELL
$5.12 - $8.48 $169,077 - $280,035
-33,023 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$3.16 - $7.03 $104,352 - $232,151
33,023 New
33,023 $192,000
Q2 2020

Aug 07, 2020

SELL
$1.58 - $4.63 $95,768 - $280,638
-60,613 Closed
0 $0
Q4 2019

Feb 04, 2020

SELL
$2.25 - $3.07 $59,382 - $81,023
-26,392 Reduced 30.33%
60,613 $166,000
Q3 2019

Nov 20, 2019

BUY
$2.67 - $3.65 $103,270 - $141,174
38,678 Added 80.03%
87,005 $256,000
Q2 2019

Aug 13, 2019

BUY
$2.6 - $4.21 $125,650 - $203,456
48,327 New
48,327 $139,000
Q3 2018

Nov 13, 2018

SELL
$1.45 - $6.15 $44,035 - $186,769
-30,369 Closed
0 $0
Q2 2018

Jul 30, 2018

BUY
$1.65 - $2.5 $12,957 - $19,632
7,853 Added 34.88%
30,369 $50,000
Q1 2018

May 14, 2018

SELL
$1.25 - $2.65 $78,807 - $167,071
-63,046 Reduced 73.68%
22,516 $42,000
Q4 2017

Feb 09, 2018

BUY
$1.23 - $2.3 $87,189 - $163,037
70,886 Added 483.01%
85,562 $111,000
Q3 2017

Nov 15, 2017

BUY
$1.95 - $2.25 $28,618 - $33,021
14,676
14,676 $0

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.